Seka Aleksić lost 22 kg with Vegovy; some patients report severe side effects
Public attention returns after the singer’s 22‑kilogram loss, while other patients report serious side effects and prolonged recovery.

Seka Aleksić has revealed she dropped 22 kilograms after starting treatment with the weight-loss drug known locally as “Vegovy”, a development that has renewed public interest in the class of GLP‑1 medications. She says the injections were only one element of a broader program that included diet adjustments and regular exercise.
Patient reports range from dramatic results to worrying side effects
“The struggle lasted for months. For years I had insulin resistance and on my endocrinologist’s recommendation I started therapy. I used certain injections, and in addition I changed my diet and began to train regularly,” Aleksić told reporters, adding that in the first seven months she lost 14 kilograms and that her main motivations were health and improved self‑confidence.
But other patients describe far harsher experiences. A 41‑year‑old woman, Valentina, said that despite having the therapy prescribed and monitored by physicians, she developed severe problems within three months. Before starting injections she had lost 17 kilograms over a year and a half through strict dieting, yet when weight loss stalled doctors recommended the drug because of Hashimoto’s disease and insulin resistance. Dose increases were performed every month with controls every two weeks.
“The nausea lasted for days but was accompanied by fainting, severe headaches, and later massive hair loss,” Valentina reported. She also said her blood pressure reached values up to 189, her diastolic pressure regularly exceeded 100, and her resting pulse often topped 100 beats per minute. After stopping the therapy she experienced a strong rebound in appetite, especially for sweets, and it took about two months for blood pressure, headaches and concentration problems to stabilise; hair loss decreased but did not stop completely.
Regional and international health outlets have flagged similar side effects linked to GLP‑1 receptor agonists (such as semaglutide, liraglutide and tirzepatide). Besides common gastrointestinal complaints — nausea, vomiting, diarrhoea, constipation and abdominal pain — users sometimes report fatigue, dizziness, scalp irritation and hair thinning. Experts note that hair loss is often explained by telogen effluvium, a temporary shedding triggered by rapid weight loss, reduced calorie and protein intake or deficiencies in iron, zinc and vitamins, although more serious but rarer complications involving the gallbladder, digestion or vision have also been observed in some cases.
Medical specialists emphasise that these drugs are indicated for specific conditions — most commonly type 2 diabetes and the treatment of excess weight or obesity — and should be used only after careful evaluation and under professional supervision. Personal testimonies do not substitute for clinical evidence, but the wide spectrum of patient experiences underlines the need for individual monitoring and caution when starting these therapies.
Photo: press material from the event


